ZA200303776B - Cosmetic method of treating skin. - Google Patents
Cosmetic method of treating skin. Download PDFInfo
- Publication number
- ZA200303776B ZA200303776B ZA200303776A ZA200303776A ZA200303776B ZA 200303776 B ZA200303776 B ZA 200303776B ZA 200303776 A ZA200303776 A ZA 200303776A ZA 200303776 A ZA200303776 A ZA 200303776A ZA 200303776 B ZA200303776 B ZA 200303776B
- Authority
- ZA
- South Africa
- Prior art keywords
- skin
- treating
- pinolenic acid
- boosting
- improving
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 18
- HXQHFNIKBKZGRP-URPRIDOGSA-N (5Z,9Z,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC\C=C/CCCC(O)=O HXQHFNIKBKZGRP-URPRIDOGSA-N 0.000 claims description 46
- HXQHFNIKBKZGRP-UHFFFAOYSA-N Ranuncelin-saeure-methylester Natural products CCCCCC=CCC=CCCC=CCCCC(O)=O HXQHFNIKBKZGRP-UHFFFAOYSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 36
- 102000004237 Decorin Human genes 0.000 claims description 20
- 108090000738 Decorin Proteins 0.000 claims description 20
- 230000000699 topical effect Effects 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 230000008901 benefit Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 206010051246 Photodermatosis Diseases 0.000 claims description 13
- 238000007665 sagging Methods 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 230000037307 sensitive skin Effects 0.000 claims description 8
- 230000004888 barrier function Effects 0.000 claims description 7
- 230000017423 tissue regeneration Effects 0.000 claims description 7
- 230000036548 skin texture Effects 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 23
- 210000002950 fibroblast Anatomy 0.000 description 18
- 239000012528 membrane Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000002500 effect on skin Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 230000008845 photoaging Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000003953 foreskin Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- -1 pinolenic acid Chemical class 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 235000019496 Pine nut oil Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000010490 pine nut oil Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical class CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000008299 Pinus lambertiana Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000045840 human DCN Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Description
COSMETIC METHOD OF TREATING SKIN
This invention relates to a cosmetic method of improving the condition and appearance of skin and to the use of pinolenic acid in the preparation of topical compositions for improving the condition and appearance of skin.
Skin is subject to deterioration through dermatological disorders, environmental abuse (wind, air conditioning, central heating) or through the normal aging process : (chronoaging) which may be accelerated by exposure of skin to sun (photoaging). In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously.
Consumers are increasingly seeking “anti-aging” cosmetic products which treat or delay the visible signs of chronoaging and photoaging skin such as wrinkles, lines, sagging, hyperpigmentation and age spots.
Consumers also frequently seek other benefits from cosmetic products in addition to anti-aging. The concept of “sensitive skin” has also raised the consumer demand for cosmetic products which improve the appearance and condition of sensitive, dry and/or flaky skin and to soothe red, and/or irritated skin. Consumers also desire cosmetic products which treat spots, pimples, blemishes etc. 300 The use of fatty acids, including pinolenic acid, in ) cosmetic formulations for treating the body is known. For example, it is known (from e.g. WO098/43513) that pine nut oil (which contains pinolenic acid) can have an antji-
inflammatory effect, where it is used to coat nail files to ' inhibit any infections caused on use of the files.
We have now surprisingly found further undisclosed properties of pinolenic acid, which are useful in cosmetic compositions for topical application to skin to provide previously undisclosed skin care benefits.
We have now found that effective treatment and prevention of normal skin conditions due to chronoaging or photoaging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, may be obtained through the application of cosmetic compositions to the skin which comprise pinolenic acid or derivatives thereof. We have also found that the use of pinolenic acid in cosmetic compositions advantageously provides further skin benefits in addition to anti-aging such as for soothing sensitive and/or irritated skin, improved resilience, reduced dryness/flakiness and reduced hyperproliferaton.
Thus, according to a first aspect of the invention, there is provided a topical composition for application to the human skin comprising an effective amount of pinolenic acid.
According to a further aspect of the present invention there is provided a cosmetic method of providing at least one skin care benefit selected from: treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen : deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and ' resilience through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; and improving skin texture, smoothness and/or firmness; the method comprising applying to the skin a topical composition comprising ’ pinolenic acid and/or derivatives thereof.
The present invention also encompasses the use of pinolenic acid and/or derivatives thereof in a topical composition for providing at least one skin care benefit selected from treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; improving skin texture, smoothness and/or firmness.
The inventive methods and use of pinolenic acid thus provide anti-aging benefits which result in the promotion of smooth and supple skin with improved elasticity and a reduced or delayed appearance of wrinkles and aged skin, with improved skin colour. A general improvement in the appearance, texture and condition, in particular with respect to the radiance, clarity, and general youthful appearance of skin may be achieved. The inventive methods and uses are also beneficial for soothing and calming sensitive and/or irritated skin. Thus the inventive methods advantageously provide a wide range of skin care benefits.
The term “treating” as used herein includes within its scope ’ reducing, delaying and/or preventing the above mentioned skin conditions such as wrinkled, aged, photodamaged, and/or ) irritated skin and generally enhancing the quality of skin and improving its appearance and texture by preventing or reducing wrinkling and increasing flexibility, firmness, smoothness, suppleness and elasticity of the skin. The cosmetic methods and the uses of pinolenic acid and/or ) derivatives according to the invention may be useful for i treating skin which is already in a wrinkled, aged, photo- damaged, dry and irritated condition or for treating youthful skin to prevent or reduce those aforementioned deteriorative changes due to the normal aging/photoaging process.
Pinoleic acid is an unsaturated long chain (C18) fatty acid, having three double bonds at the 5,9, and 12 positions. It may be found in e.g. pine nut oil at levels of around 25%.
The invention also includes derivatives of the free acid which thus comprise pinolenic acid moieties. Preferable derivatives include those derived from substitution of the carboxyl group of the acid, such as esters (eg retinyl esters, triglyceride esters, monoglyceride esters, diglyceride esters, phosphoesters), amides (eg ceramide derivatives), salts (eg alkali metal and alkali earth metal salts, ammonium salts); and/or those derived from substitution of the C18 carbon chain, such as alpha hydroxy and/or beta hydroxy derivatives.
In the case of triglyceride ester derivatives, all positional isomers of pinolenic acid substituents on the glycerol backbone are included. The triglycerides must contain at least one pinolenic acid moiety. For example, of the three esterifiable positions on the glycerol backbone, ' the 1 and 2 positions may be esterified with pinolenic acid and by another lipid at position 3 or as an alternative, the glycerol backbone could be esterified by PA at the 1 and 3 positions with another lipid at position 2.
Oils that may be rich in pinolenic acid triglyceride would ’ thus also suitable for use in the present invention.
Wherever the term “pinolenic” is used in this specification it is to be understood that the derivatives thereof comprising pinolenic moieties are also included. “pinolenic acid moieties” refers to pinolenic fatty acyl portion(s) of a pinolenic derivative.
The active, pinolenic acid, to be employed in accordance with the present invention is present in the topical composition in an effective amount. Normally the total amount of the active is present in an amount between 0.0001% and 50% by weight of the composition. More preferably the amount is from 0.01% to 10% and most preferably from 0.1% to 5% in order to maximise benefits at a minimum cost.
The composition used according to the invention also comprises a dermatologically/cosmetically acceptable vehicle to act as a dilutant, dispersant or carrier for the active pinolenic acid or its derivative. The vehicle may comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellants and the like.
The vehicle will usually form from 5% to 99.9%, preferably from 25% to 80% by weight of the composition, and can, in ’ the absence of other cosmetic adjuncts, form the balance of the composition.
Besides the active, pinolenic acid, other specific skin- benefit actives such as sunscreens, other skin lightening agents, skin tanning agents may also be included. The
-— © _ vehicle may also further include adjuncts such as perfumes, opacifiers, preservatives, colourants and buffers.
To prepare the topical composition used in the method of the present invention, the usual manner for preparing skin care products may be employed. The active components are generally incorporated in a dermatologically acceptable carrier in conventional manner. The active components can suitably first be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition. The preferred compositions are oil-in-water or water-in-oil emulsions.
The composition may be in the form of conventional skin-care products such as a cream, gel or lotion or the like. The composition can also be in the form of a so-called “wash- off” product e.g. a bath or shower gel, possibly containing a delivery system for the actives to promote adherence to the skin during rinsing. Most preferably the product is a “leave-on” product; a product to be applied to the skin without a deliberate rinsing step soon after its application to the skin.
The composition may packaged in any suitable manner such as in a Jar, a bottle, tube, roll-ball, or the like, in the conventional manner.
The method of the present invention may be carried out one or more times daily to the skin which requires treatment.
The improvement in skin appearance will usually become visible after 3 to 6 months, depending on skin condition, the concentration of the active components used in the inventive method, the amount of composition used and the frequency with which it is applied. In general, a small quantity of the composition, for example from 0.1 to 5 ml is applied to the skin from a suitable container or applicator . and spread over and/or rubbed into the skin using the hands or fingers or a suitable device. A rinsing step may optionally follow depending on whether the composition is formulated as a “leave-on” or a “rinse-off” product.
In order that the present invention may be more readily understood, the following examples are given, by way of illustration only.
The invention will now be explained by way of example only with reference to the accompanying figures, in which; - Figures 1 and 2 show the effect of pinolenic acid on decorin and procollagen I upregulation; - Figures 3 and 4 demonstrate the effect of pinolenic acid on stimulated PGE2 levels in fibroblasts and on
PMA stimulated sICAM-1 levels in fibroblasts; - Figure 5 shows the effect of pinolenic acid on cornified envelope formation; and - Figure 6 shows the effect of pinolenic acid on keratinocyte differentiation.
Co
The following example demonstrates the anti-aging benefits of pinolenic acid.
It is know from our co-pending European application No. 99908956.8 that topical retinoic acid treatments can be used to cause upregulation of procollagen I and decorin in vivo.
To this end, the passages under the heading “Identification of procollagen I and decorin upregulation in skin in vivo ) following topical retinoic acid treatment for comparative purposes” in that application are incorporated herein in their entirety.
Example 1
Procedure For Measuring Procollagen-I and Decorin Synthesis
In Human Dermal Fibroblasts
Preparation of Dermal Fibroblast Conditioned Medium
Primary human foreskin fibroblasts at passage 2 (P2) were seeded into 12-well plates at 10000 cells/cm? and maintained for 24 hours in an atmosphere of 5% carbon dioxide and 4% oxygen in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum. After this time the cells were washed with serum free DMEM and then incubated in fresh serum free DMEM for a further 60 hours.
The fibroblast monolayers were then washed again with serum free DMEM. Test reagents and vehicle controls were added to the cells in triplicate in a final volume of 0.4ml/well fresh serum free DMEM and incubated for a further 24 hours.
This fibroblast conditioned medium was either analysed immediately or snap frozen in liquid nitrogen and stored at -70°C for future analysis. The cells were then counted and } data from the dot-blot analysis subsequently standardised to cell number. . 30
Dot Blot Assay for Procollagen-I and Decorin Protein in
Dermal Fibroblast Conditioned Medium
- 0g -
Samples of conditioned medium from dermal fibroblasts treated with vehicle (as a control) or test reagents were supplemented with 20mM dithiothreitol (1:10 dilution of 200mM stock solution) and 0.1% sodium dodecylsulphate (1:100 dilution of 10% stock solution), mixed well and then incubated at 75°C for 2 minutes. A standard for the assay was generated by serial dilution of neat fibroblast conditioned medium from fibroblasts seeded at 10000 cells/cm? in a 175cm’ flask and maintained in serum free DMEM as described above.
Assay samples were subsequently applied in triplicate to a pre-wetted sheet of Immobilon-P transfer membrane using the 96-well Bio-Dot Apparatus from Bio-Rad as described in the manufacturers’ guidelines. Approximately 200ul of medium was applied per well. The medium was allowed to filter through the membrane under gravity (30 minutes) after which the membrane was washed twice with PBS (200pl). These PBS washes were allowed to filter through the membrane under gravity (2x15 minutes). The Bio—-Dot apparatus was then attached to a vacuum manifold and a third and final PBS wash carried out under suction. The apparatus was disassembled, the membrane removed and quickly cut as required before being placed in blocking buffer overnight at 4°C. :
Membranes prepared for decorin analysis were blocked with 3% (w/v) BSA/ 0.1% (v/v) Tween 20 in PBS, whilst those for , procollagen-I analysis were blocked with 5% (w/v) non fat dried milk powder/ 0.05% Tween 20 in PBS. The following . 30 day, the membranes were probed with 1:10000 dilution of primary antibodies to either human procollagen-I (MAB1912; rat monoclonal; Chemicon Int. Inc., Temecula, CA) or human decorin (rabbit polyclonal; Biogenesis) for 2 hours at room temperature. The membranes were subsequently washed with
TBS/ 0.05% Tween 20 (3 x 5 minutes) and then incubated with 1:1000 dilution of *%I-conjugated anti-rat or anti-rabbit
F(ab')2 fragments (Amersham) as required for 1 hour at room temperature.
Following this the Immobilon strips were again washed with
TBS/Tween 20 (3 x 5 minutes) before being allowed to dry in air at room temperature. The dried membranes were wrapped in cellophane and exposed to a Molecular Dynamics storage phosphor screen for 16-18 hours. At the end of this time the exposed screen was scanned by a phosphorimager (Mclecular
Dynamics Phosphorimager SF) using ImageQuant™ software. Dot intensity was assessed by computer-assisted image analysis using the quantification tools in ImageQuant™, standardised to cell number and the effects of various test reagents on decorin and procollagen—-I synthesis were determined relative to a vehicle treated control value of 100 arbitrary units.
Table 1 below indicates the effects of pinolenic acid on procollagen~-I and decorin synthesis in human dermal fibroblasts, and the amounts in which it was applied. In order to normalise the results the effects of the test substance was determined relative to a vehicle treated control value of 100 arbitrary units. Figures 1 and 2 show the results for more data points graphically.
For comparison, a trial was performed with retinoic acid to assess its effect on decorin synthesis in human dermal . 30 fibroblasts. The concentrations of reagents used in the trials had no influence on cell viability.
Table 1 - The Effect on Procollagen-I and Decorin Synthesis by Pinolenic Acid
I
Pinolenic Acid (10uM) 148.2+2.3 119.0+£6.9 (n=3) (n=3)
The results in table 1 indicate that pinolenic acid significantly upregulates the synthesis of both procollagen-
I and decorin in human dermal fibroblasts as compared to the control.
The level of decorin in skin is associated with improved condition and appearance of skin. Increasing the level of decorin in skin is important for controlled and correct deposition of collagen in skin which is associated with many skin benefits such as wrinkle effacement and dermal repair of photodamaged skin.
Example 2
This example measures the effect of pinolenic acid on reducing the inflammatory response of dermal fibroblasts.
Fibroblasts PGE» and ICAM Assay
Intracellular adhesion molecules (ICAM) and PEG; production . by human skin fibroblasts can be induced by the inflammatory stimulus PMA (phorbal myristate acetate). PMA represents an external stressor which induces oxidative stress and inflammatory responses in cells. This model is used to ‘ model inflammation in vivo. ‘ Primary human foreskin fibroblasts at passage 2 (P2) were seeded into 96-well plates at 35,000 cells/well and maintained for 24 hours in an atmosphere of 5% carbon dioxide in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum. Pinolenic acid was added to fresh cell media (DMEM, supplemented with 10% foetal calf serum) in dimethylsulphoxide (ethanol, final concentration 1%) in triplicate and incubated for a further 24 hours. Phorbal myristate acetate (PMA), 10nM (Sigma) was added to the media and the cells incubated for a further 24 hours. The control did not contain any test compounds nor any PMA. The fibroblasts/media were then analysed as described below immediately or snap frozen in liquid nitrogen and stored at -70°C for future analysis. The cells were then counted and data from the dot-blot analysis subsequently standardised to cell number.
Prostaglandin E2 (PGE;) assay: Volumes of 50 pl culture medium were taken for PGE, assay after gently shaking the culture plate. PGE, levels in the medium were determined with a Biotrak PGE; immunoassay kit (Amersham, UK). The assay is based on the competition between unlabelled PGE; in the sample and a fixed quantity of horseradish peroxidase . labeled PGE for a limited amount of fixed PGE, specific antibody. Concentrations of unlabelled sample PGE; are determined according to a standard curve which was obtained at the same time.
- 13 = ) ICAM-~1 assay: Media were discarded and cells washed with
Dulbecco PBS. To the washed cells, 150 pl 0.1% Triton X-100 . (Sigma) was added for 3 minutes to extract ICAM from cell membrane. The extracts were transferred to Eppendoff centrifuge tubes and centrifuged at 1000 g for 2 min to remove cell debris. A volume of 100 pl supernatant was used for ICAM assay. The soluble ICAM-1 was assessed with commercially available immunocenzymometric assay kit (R&D
Systems) . Concentrations of ICAM-1 in the samples were determined based on parallel running standard curve.
The results that were obtained from the PGE, and ICAM assay . are summarised in table 2 below, and shown graphically in
Figures 3 and 4.
Table 2 - Effects of pinolenic acid on PMA-induced ICAM and
PGE2 production in human skin fibroblasts
EATER IW [iow Ga/al rom, ajay
I BE
* maxiumum level detectable by enzyme immunoassay : The above results show that challenging cells with an ) 25 inflammatory stimulus such as PMA (Phorbol myristyl acetate) causes an increase in the inflammatory response as measured by prostaglandin EZ (PGE) production. Pinolenic acid, even
. at the levels of 0.11pm, dramatically reduces the inflammatory response as measured by PGE; production. The ¢ results thus demonstrates that pinolenic acid has good anti- inflammatory activity.
The above results also demonstrate that challenging cells with PMA causes an increase in ICAM production. Pinolenic acid decreases the production of Intracellular adhesion molecule (ICAM), which is another marker of inflammation.
These results thus further demonstrate that pinolenic acid has good anti-inflammatory action.
Example 3
Human foreskin keratinocytes at passage 3 (P3) were seeded into 96 well plates at 4000 cells/well in Dubleccos Modified
Eagles Medium (DMEM), 0.03mM calcium. The cells were grown for 3 days prior to treatment. The treatment vehicle was
DMSO. After 4 days of treatment, the cells were harvested and washed three times with 100pl phosphate buffered saline (PBS) . The cells were then extracted in 1% Triton X100, 50mM Tris pH 8.0, 0.02mM Leupeptin, 0.02mM Pepstatin. 60pl/well of extract was then assayed for DNA concentration (ng/well), Pico Green DNA assay, Molecular Probes.
The cells were then washed in 200ul PBS, and then 100pl of 2% SDS, 20mM DTT was added to each well. The plates were ’ then sealed with a Titertek plate sealer (ICN) and incubated at 60°C over night in an air tight damp environment (i.e. a . 30 sealed sandwich box lined with damp paper). The extract was then filtered through a PVDF transfer membrane (Bio-rad) under gravity using Dot-Blot apparatus (Bio-rad). The membrane is then washed in distilled water prior to silver staining (Bio-rad Silver Stain kit). The stained dot blot ‘ membrane is then analysed using Phoretix array software (Phoretix International).
RESULTS
AY
The results are shown in Table 3 below, and graphically in figures 5 and 6.
Table 3
PM Pinolenic Acid [Mean [SD [Mean [sD 10 36579 (p=0 | 9286 12.6 0.3 .006%) 20 34374 (p=0 | 5692 12.4 0.1 .018%*) * relative to zero value. For the DNA values P<0.001.
The results show how cornified envelope production increased and DNA levels decreased in response to 0.1-20 uM application of pinolenic acid. This is indicative of enhanced keratinocyte differentiation, and suggests that pinolenic acid improves in situ skin barrier formation and resilience, and reduces trans-epidermal water loss and keratinocyte proliferation.
* Example 4 ) The formulation below describes an oil in water cream suitable for the methods and uses according to the present invention. The percentages indicated are by weight of the composition.
LR
Butylated hydroxy toluene [oor : *Brij 56 is cetyl alcohol POE (10) ** Alfol 16RD is cetyl alcohol
’ Example 5 * The formulation below describes an emulsion cream according to the present invention.
FULL CHEMICAL TRADE NAME WT. %
NAME OR CTFA NAME
Pinolemic acid | 50 oifieae, ommumieesmm tess 10° silicate [propyl paraben NF | bropylparaben NF [0.1 [glyceryl hydrostearate |Naturechem GMHS [1.5 [stearyl alcohol __ |Lanmette 18 DEO [1.5
Teostearyl panitate Ierotacken 1p leo
Cl2-15 alcohols | Hetester FAO 3.0 octancate ooroie|Retester O20 [Dimethicone Silicone Fluid 200[1.0 a = aa I Butylated Embanox BHT 0.05 vivomytoluene |oooner E00 octylare coowortjrememie ss °° lactylate
Hydroxycaprylic acid [Hydroxycaprylic Acid [0.1 retinyl palmitate [Vitamin A Palmitate _ ]0.06
EL RE | 0
: Both the above topical compositions of examples 4 and 5 provide an effective cosmetic treatment to improve the * appearance of wrinkled, aged, photo-damaged, and/or irritated skin, when applied to skin that has deteriorated through the aging or photoaging or when applied to youthful skin to help prevent or delay such deteriorative changes.
The compositions can be processed in conventional manner.
Claims (7)
1. A topical composition comprising: (a) an effective amount of pinolenic acid; and (b) a dermatologically acceptable vehicle.
2. A topical composition according to claim 1, wherein the pinolenic acid is present in the topical composition at a level of 0.1 to 5% by weight of the topical composition.
3. A cosmetic method of providing at least one skin care benefit selected from: treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; and improving skin texture, smoothness and/or firmness; the method comprising applying to the skin a topical composition comprising pinolenic acid and/or derivatives thereof.
4. Use of pinolenic acid and/or derivatives thereof in a ) topical composition for providing at least one skin care benefit selected from treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience through enhanced barrier formation; treating
-— 2 0 — * dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; improving skin ) texture, smoothness and/or firmness.
5. Use of pinolenic acid and/or derivatives thereof in the prparation of a topical composition for providing at least one skin care benefit selected from treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; and improving skin texture, smoothness and/or firmness.
6. Pinolenic acid and/or derivatives thereof for use in treating/preventing wrinkling, sagging, + aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing irritated, red and/or sensitive skin; and improving skin texture, smoothness and/or firmness.
7. A topical composition comprising: (i) an effective amount - of pinolenic acid and/or derivatives thereof; and (ii) a cosmetically and/or dermatologically acceptable vehicle ‘ 30 for use in treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin, enhancing tissue repair; improving skin condition and resilience
- 21 = ‘ through enhanced barrier formation; treating dry and flaky skin; reduced hyperproliferation; soothing ‘ irritated, red and/or sensitive skin; and improving skin texture, smoothness and/or firmness.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0028355.6A GB0028355D0 (en) | 2000-11-21 | 2000-11-21 | Cosmetic method of treating skin |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303776B true ZA200303776B (en) | 2004-05-17 |
Family
ID=9903574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303776A ZA200303776B (en) | 2000-11-21 | 2003-05-15 | Cosmetic method of treating skin. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1337235A1 (en) |
JP (1) | JP2004523488A (en) |
KR (1) | KR20030062349A (en) |
CN (1) | CN1486174A (en) |
AU (2) | AU2002220694B2 (en) |
CA (1) | CA2428634A1 (en) |
GB (1) | GB0028355D0 (en) |
MX (1) | MXPA03004449A (en) |
WO (1) | WO2002041865A1 (en) |
ZA (1) | ZA200303776B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1506042A (en) * | 2002-12-11 | 2004-06-23 | 苏加璐 | Method and composition for improving skin state using compound from fetal cell and tissue |
JP2004224742A (en) * | 2003-01-23 | 2004-08-12 | Umeken:Kk | Skin care preparation |
JP2007063195A (en) * | 2005-08-31 | 2007-03-15 | Katakura Chikkarin Co Ltd | Bleaching agent and external preparation for skin containing the same |
HU227970B1 (en) | 2007-07-10 | 2012-07-30 | Egis Gyogyszergyar Nyrt | Pharmaceutical compositions containing silicones of high volatility |
GB0814105D0 (en) * | 2008-08-01 | 2008-09-10 | Springdale Sustainable Develop | Composition for accelerated production of collagen |
US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6163610A (en) * | 1984-09-05 | 1986-04-01 | Nisshin Oil Mills Ltd:The | Cosmetic |
FR2756465B1 (en) * | 1996-12-03 | 1999-02-19 | D A Noste | FOOD ADDITIVE, COSMETIC COMPOSITION AND MEDICINAL PRODUCT BASED ON PINE SEED OIL |
GB9918023D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
ES2265865T3 (en) * | 1999-09-30 | 2007-03-01 | Loders Croklaan B.V. | COMPOSITIONS CONTAINING PINOLENIC ACID AND ITS USE AS A COMPONENT FOR HEALTH. |
-
2000
- 2000-11-21 GB GBGB0028355.6A patent/GB0028355D0/en not_active Ceased
-
2001
- 2001-11-07 EP EP01997293A patent/EP1337235A1/en not_active Withdrawn
- 2001-11-07 WO PCT/EP2001/013039 patent/WO2002041865A1/en not_active Application Discontinuation
- 2001-11-07 JP JP2002544044A patent/JP2004523488A/en not_active Withdrawn
- 2001-11-07 AU AU2002220694A patent/AU2002220694B2/en not_active Ceased
- 2001-11-07 AU AU2069402A patent/AU2069402A/en active Pending
- 2001-11-07 KR KR10-2003-7006789A patent/KR20030062349A/en not_active Application Discontinuation
- 2001-11-07 CA CA002428634A patent/CA2428634A1/en not_active Abandoned
- 2001-11-07 MX MXPA03004449A patent/MXPA03004449A/en unknown
- 2001-11-07 CN CNA018221610A patent/CN1486174A/en active Pending
-
2003
- 2003-05-15 ZA ZA200303776A patent/ZA200303776B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20030062349A (en) | 2003-07-23 |
CN1486174A (en) | 2004-03-31 |
EP1337235A1 (en) | 2003-08-27 |
AU2069402A (en) | 2002-06-03 |
GB0028355D0 (en) | 2001-01-03 |
WO2002041865A1 (en) | 2002-05-30 |
JP2004523488A (en) | 2004-08-05 |
AU2002220694B2 (en) | 2005-02-10 |
MXPA03004449A (en) | 2003-08-19 |
CA2428634A1 (en) | 2002-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1198221B1 (en) | Skin care composition | |
CZ20012333A3 (en) | Cosmetic preparation | |
EP1061896B1 (en) | Cosmetic method of treating skin | |
AU2002324040B2 (en) | Cosmetic composition and method of treating skin | |
US6042841A (en) | Cosmetic method of treating skin | |
AU774422B2 (en) | Skin care composition containing petroselinic acid | |
EP1333805B1 (en) | Cosmetic method of treating skin | |
AU2002324040A1 (en) | Cosmetic composition and method of treating skin | |
AU2002220694B2 (en) | Cosmetic method of treating skin | |
AU2002221758B2 (en) | Skin treatment composition and method based on the use of chromolaena odorata | |
US20030099677A1 (en) | Cosmetic composition and method of treating skin | |
MXPA00008982A (en) | Cosmetic method of treating skin | |
AU2002324039A1 (en) | Cosmetic composition and method of treating skin |